Alcami Acquires Tjoapack to Expand Packaging and Enter Europe

Alcami Corporation, a leading U.S.-based contract development and manufacturing organization (CDMO) backed by GHO Capital Partners, The Vistria Group, and Ampersand Capital Partners, has entered into a definitive agreement to acquire Tjoapack, a global contract packaging organization (CPO) majority-owned by Ampersand Capital Partners, with operations in the United States and The Netherlands. The deal, announced on April 21, 2026, represents Alcami’s first expansion into the European market and aims to enhance its integrated pharmaceutical services. Financial terms remain undisclosed, with closing expected in Q2 2026 subject to customary conditions. Notably, Ampersand Capital Partners will reinvest as part of the transaction, maintaining a stake in the combined entity and signalling continued conviction in the platform’s growth trajectory.

Tjoapack, founded in 1989 and headquartered in Etten-Leur, The Netherlands, specialises in primary and secondary packaging solutions for the pharmaceutical and biotechnology sectors. Its services span packaging and labelling for oral solid doses including blister packs and bottles, as well as sterile injectables including vials, pre-filled syringes, and auto-injectors. The company operates 23 packaging lines across facilities in Clinton, Tennessee, and Etten-Leur, employing over 400 skilled personnel and serving more than 40 commercial markets worldwide.

For Alcami, the acquisition delivers two strategic imperatives simultaneously: enhanced U.S. supply chain redundancy and scale in packaging and labelling, and a direct entry into the European market with Qualified Person (QP) release and related regulatory services. Customers will benefit from a more comprehensive, integrated offering — combining Alcami’s pharmaceutical testing labs, drug product manufacturing, and GMP pharma storage with Tjoapack’s packaging capabilities, facilitating global drug delivery with fewer supplier hand-offs.

Patrick Walsh, Chairman and CEO of Alcami, described the deal as an essential element of the company’s investment strategy to expand its global presence, highlighting alignment with Alcami’s growth in pharmaceutical testing, drug product manufacturing, and pharma storage services. Dexter Tjoa, CEO of Tjoapack, emphasised that the partnership with Alcami will accelerate Tjoapack’s growth ambitions while staying true to the quality, reliability, and customer focus that has defined the business — together creating a more integrated transatlantic platform to support partners as they scale globally.

The acquisition is expected to generate multiple synergies through cross-selling opportunities combining Alcami’s CDMO services with Tjoapack’s packaging capabilities, supply chain consolidation across U.S. and European sites, and standardised quality and compliance processes. The combined entity is poised to compete more effectively in a consolidating contract pharmaceutical services sector, strengthening Alcami’s position as a comprehensive CDMO with an expanded geographic footprint.

Alcami Corporation, headquartered in Wilmington, North Carolina, has over 45 years of experience in advancing pharmaceuticals and biologics from development through delivery, backed by GHO Capital Partners, The Vistria Group, and Ampersand Capital Partners. Tjoapack operates GMP-compliant facilities in Europe and the U.S., supported by 35+ years of contract packaging expertise.